AU2018226771B2 - Uses of pyrimidopyrimidinones as SIK inhibitors - Google Patents

Uses of pyrimidopyrimidinones as SIK inhibitors Download PDF

Info

Publication number
AU2018226771B2
AU2018226771B2 AU2018226771A AU2018226771A AU2018226771B2 AU 2018226771 B2 AU2018226771 B2 AU 2018226771B2 AU 2018226771 A AU2018226771 A AU 2018226771A AU 2018226771 A AU2018226771 A AU 2018226771A AU 2018226771 B2 AU2018226771 B2 AU 2018226771B2
Authority
AU
Australia
Prior art keywords
substituted
unsubstituted
alkyl
certain embodiments
instance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018226771A
Other languages
English (en)
Other versions
AU2018226771A1 (en
Inventor
Hwan Geun Choi
David E. Fisher
Nathanael S. Gray
Yanke LIANG
Nisma MUJAHID
Ryo Murakami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Dana Farber Cancer Institute Inc
Original Assignee
General Hospital Corp
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Dana Farber Cancer Institute Inc filed Critical General Hospital Corp
Publication of AU2018226771A1 publication Critical patent/AU2018226771A1/en
Application granted granted Critical
Publication of AU2018226771B2 publication Critical patent/AU2018226771B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2018226771A 2017-02-28 2018-02-28 Uses of pyrimidopyrimidinones as SIK inhibitors Active AU2018226771B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762464675P 2017-02-28 2017-02-28
US62/464,675 2017-02-28
US201762472468P 2017-03-16 2017-03-16
US62/472,468 2017-03-16
PCT/US2018/020335 WO2018160774A1 (en) 2017-02-28 2018-02-28 Uses of pyrimidopyrimidinones as sik inhibitors

Publications (2)

Publication Number Publication Date
AU2018226771A1 AU2018226771A1 (en) 2019-09-19
AU2018226771B2 true AU2018226771B2 (en) 2023-11-23

Family

ID=63370223

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018226771A Active AU2018226771B2 (en) 2017-02-28 2018-02-28 Uses of pyrimidopyrimidinones as SIK inhibitors

Country Status (10)

Country Link
US (3) US11285158B2 (enExample)
EP (1) EP3589284A4 (enExample)
JP (2) JP7296318B2 (enExample)
KR (1) KR20190120331A (enExample)
CN (1) CN111163771B (enExample)
AU (1) AU2018226771B2 (enExample)
BR (1) BR112019017741A2 (enExample)
CA (1) CA3054809A1 (enExample)
RU (1) RU2019129727A (enExample)
WO (1) WO2018160774A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10287268B2 (en) 2014-07-21 2019-05-14 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
US10954242B2 (en) * 2016-07-05 2021-03-23 The Broad Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof
WO2018053373A1 (en) 2016-09-16 2018-03-22 The General Hospital Corporation Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis
CN111163771B (zh) * 2017-02-28 2023-07-14 通用医疗公司 嘧啶并嘧啶酮类作为sik抑制剂的用途
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
AU2019413683B2 (en) * 2018-12-28 2025-05-22 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
HUE065486T2 (hu) 2019-05-10 2024-05-28 Deciphera Pharmaceuticals Llc Fenilaminopirimidinamid autophágia inhibitorok és azok felhasználási eljárásai
PL3966206T3 (pl) 2019-05-10 2024-01-29 Deciphera Pharmaceuticals, Llc Heteroaryloaminopirymidynoamidowe inhibitory autofagii i sposoby ich zastosowania
AU2020297422B2 (en) * 2019-06-17 2024-03-21 Deciphera Pharmaceuticals, Llc Aminopyrimidine amide autophagy inhibitors and methods of use thereof
PH12022550361A1 (en) 2019-08-14 2023-02-27 Incyte Corp Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
PE20221905A1 (es) 2019-10-11 2022-12-23 Incyte Corp Aminas biciclicas como inhibidoras de la cdk2
EP3901151A1 (en) 2020-04-21 2021-10-27 iOmx Therapeutics AG Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof
WO2021219731A2 (en) 2020-04-28 2021-11-04 Iomx Therapeutics Ag Bicyclic kinase inhibitors and uses thereof
AU2021343539A1 (en) * 2020-09-21 2023-05-18 Soltego, Inc. Sik inhibitors and methods of use thereof
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
CN118369321A (zh) 2021-10-19 2024-07-19 艾奥麦克斯治疗公司 制备sik3抑制剂及其中间体的合成方案和程序
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN114414681B (zh) * 2021-12-30 2024-10-11 珠海天祥粤澳质量技术服务有限公司 一种同时测定化妆品中的多种色素的方法
EP4257132A1 (en) 2022-04-08 2023-10-11 iOmx Therapeutics AG Sik3 inhibitors for treating diseases resistant to death receptor signalling
JP2025517351A (ja) * 2022-05-17 2025-06-05 ソルテゴ， インコーポレイテッド ピリミドピリミドン化合物およびその使用方法
WO2025059216A1 (en) * 2023-09-12 2025-03-20 Dana-Farber Cancer Institute, Inc. Treatment of high-grade serous carcinoma
WO2025157389A1 (en) 2024-01-22 2025-07-31 Iomx Therapeutics Ag Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors
CN118546871B (zh) * 2024-05-10 2025-05-06 未来智人再生医学研究院(广州)有限公司 一种人多能干细胞分化为间充质干细胞的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016023014A2 (en) * 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Uses of salt-inducible kinase (sik) inhibitors
WO2018009544A1 (en) * 2016-07-05 2018-01-11 The Broad Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4231559B2 (ja) 1997-04-23 2009-03-04 オリザ油化株式会社 リポキシゲナーゼ阻害剤
ES2310039T3 (es) 1998-05-26 2008-12-16 Warner-Lambert Company Llc Pirimidinas biciclicas y 3,4-dihidropirimidinas biciclicas como inhibidores de la proliferacion celular.
WO2000024744A1 (en) 1998-10-23 2000-05-04 F. Hoffmann-La Roche Ag Bicyclic nitrogen heterocycles
CA2388142C (en) 1999-10-21 2008-12-09 F. Hoffmann-La Roche Ag Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
AU2003225161A1 (en) * 2002-04-24 2003-11-10 Koo, Han-Mo Enhancement of human epidermal melanogenesis
US7084270B2 (en) 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
WO2004018669A1 (ja) 2002-08-21 2004-03-04 Proteinexpress Co., Ltd. 塩誘導性キナーゼ２及びその用途
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
US7129351B2 (en) 2002-11-04 2006-10-31 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
WO2004048343A1 (en) 2002-11-28 2004-06-10 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
WO2004089955A1 (en) 2003-04-10 2004-10-21 F.Hoffmann-La Roche Ag Pyrimido compounds
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
CN1860118A (zh) 2003-07-29 2006-11-08 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
RU2401265C2 (ru) 2004-06-10 2010-10-10 Айрм Ллк Соединения и композиции в качестве ингибиторов протеинкиназы
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
KR100853975B1 (ko) 2004-08-31 2008-08-25 에프. 호프만-라 로슈 아게 3-페닐 디히드로피리미도[4,5-ｄ]피리미디논의 아미드유도체, 이의 제조 방법 및 약제로서의 용도
WO2006024545A1 (en) 2004-09-03 2006-03-09 Stichting Voor De Technische Wetenschappen Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes
US8211929B2 (en) 2004-12-30 2012-07-03 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
JP2008537937A (ja) 2005-03-25 2008-10-02 グラクソ グループ リミテッド ピリド［２，３−ｄ］ピリミジン−７−オンおよび３，４−ジヒドロピリミド［４，５−ｄ］ピリミジン−２（１Ｈ）−オン誘導体の製造方法
CN101336237B (zh) 2005-12-21 2015-09-30 诺华股份有限公司 作为fgf抑制剂的嘧啶基芳基脲衍生物
EP2018167A4 (en) 2006-05-15 2010-07-14 Irm Llc COMPOSITIONS AND METHODS AS INHIBITORS OF FGF RECEPTOR KINASES
WO2008060248A1 (en) 2006-11-15 2008-05-22 S*Bio Pte Ltd. Indole sustituted pyrimidines and use thereof in the treatment of cancer
ES2734288T3 (es) 2007-11-28 2019-12-05 Dana Farber Cancer Inst Inc Inhibidores de miristato de moléculas pequeñas de Bcr-abl y métodos de uso
WO2009122180A1 (en) 2008-04-02 2009-10-08 Medical Research Council Pyrimidine derivatives capable of inhibiting one or more kinases
WO2009152027A1 (en) 2008-06-12 2009-12-17 Merck & Co., Inc. 5,7-dihydro-6h-pyrrolo[2,3-d]pyrimidin-6-one derivatives for mark inhibition
JP2011530511A (ja) 2008-08-05 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション 治療用化合物
JP2013508285A (ja) 2009-10-14 2013-03-07 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎の処置のための組成物
CN102816162B (zh) * 2011-06-10 2016-04-27 中国科学院广州生物医药与健康研究院 嘧啶并嘧啶酮类化合物及其药用组合物和应用
EA025881B1 (ru) 2011-09-30 2017-02-28 Онкодизайн С.А. Макроциклические ингибиторы flt3-киназы
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
GB201204384D0 (en) 2012-03-13 2012-04-25 Univ Dundee Anti-flammatory agents
EP2841428B1 (en) 2012-04-24 2018-08-22 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
US9260426B2 (en) * 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
CN105209040A (zh) 2013-03-15 2015-12-30 昂科迪塞恩股份有限公司 大环的盐可诱导的激酶抑制剂
AU2014228746B2 (en) 2013-03-15 2018-08-30 Celgene Car Llc Heteroaryl compounds and uses thereof
AU2014287209B2 (en) * 2013-07-09 2019-01-24 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
US10457691B2 (en) 2014-07-21 2019-10-29 Dana-Farber Cancer Institute, Inc. Macrocyclic kinase inhibitors and uses thereof
US10287268B2 (en) 2014-07-21 2019-05-14 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
KR101850282B1 (ko) 2014-11-26 2018-05-31 한국과학기술연구원 단백질 키나아제 저해제로 유용한 헤테로아릴아민 유도체
CN104482860B (zh) 2014-12-05 2017-10-31 浙江大学宁波理工学院 鱼类形态参数自动测量装置和方法
WO2018053373A1 (en) 2016-09-16 2018-03-22 The General Hospital Corporation Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis
CN111163771B (zh) * 2017-02-28 2023-07-14 通用医疗公司 嘧啶并嘧啶酮类作为sik抑制剂的用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016023014A2 (en) * 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Uses of salt-inducible kinase (sik) inhibitors
WO2018009544A1 (en) * 2016-07-05 2018-01-11 The Broad Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AYAKO KUMAGAI ET AL: PLOS ONE, vol. 6, no. 10, 1 January 2011 (2011-01-01), pages e26148, XP055061161, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0026148 *
NANAO HORIKE ET AL: PIGMENT CELL & MELANOMA RESEARCH, vol. 23, no. 6, 24 September 2010 (2010-09-24), United States, Denmark, pages 809 - 819, XP055745794, ISSN: 1755-1471, DOI: 10.1111/j.1755-148X.2010.00760.x *
THOMAS B. SUNDBERG ET AL: ACS CHEMICAL BIOLOGY, vol. 11, no. 8, 19 August 2016 (2016-08-19), pages 2105 - 2111, XP055406549, ISSN: 1554-8929, DOI: 10.1021/acschembio.6b00217 *

Also Published As

Publication number Publication date
KR20190120331A (ko) 2019-10-23
JP2023088968A (ja) 2023-06-27
JP2020509022A (ja) 2020-03-26
CN111163771A (zh) 2020-05-15
AU2018226771A1 (en) 2019-09-19
JP7296318B2 (ja) 2023-06-22
EP3589284A1 (en) 2020-01-08
EP3589284A4 (en) 2020-12-16
BR112019017741A2 (pt) 2020-04-07
WO2018160774A1 (en) 2018-09-07
CA3054809A1 (en) 2018-09-07
US20220133736A1 (en) 2022-05-05
US11285158B2 (en) 2022-03-29
US11878019B2 (en) 2024-01-23
RU2019129727A (ru) 2021-03-30
RU2019129727A3 (enExample) 2021-07-02
US20240245695A1 (en) 2024-07-25
CN111163771B (zh) 2023-07-14
US20200253981A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
AU2018226771B2 (en) Uses of pyrimidopyrimidinones as SIK inhibitors
JP7308146B2 (ja) インターロイキン１受容体関連キナーゼの阻害剤およびその使用
EP3024327B1 (en) Inhibitors of transcription factors and uses thereof
JP7258748B2 (ja) サイクリン依存性キナーゼ１２（ｃｄｋ１２）の阻害剤およびその使用
JP7590185B2 (ja) Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
JP7660063B2 (ja) サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用
JP7675070B2 (ja) 治療、特にｍｙｄ８８変異疾患における使用のためのｈｃｋ阻害剤としてのピラゾロピリミジン誘導体
JP7643874B2 (ja) がん幹細胞を標的化するがん治療
JP2016505001A (ja) Ｐｒｍｔ５阻害剤およびその使用
JP2018522867A (ja) 縮合二環式ピリミジン誘導体およびこれらの使用
JP2018531987A (ja) Ｍａｌｔ１阻害剤およびその使用
JP2016531899A (ja) 二環式アルキン誘導体およびその使用
WO2014088519A1 (en) Compounds including map kinase interacting kinases 1 and 2 (mnk1 and mnk2) modulators and abl and abl (t315i) inhibitors, and uses thereof
JP2021529174A (ja) Ｄｏｔ１ｌディグレーダーおよびその使用
BR122024027123A2 (pt) Usos de pirimidopirimidinonas como inibidores de sik
WO2025213129A1 (en) Novel small molecule inhibitors of interleukin-4 and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)